Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityNo recent work listed

Qihan Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2967-1812; OpenAlex author ID A5046579422. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 3 papers

Papers 9

  1. Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study. Co-author DOI 10.1093/gastro/goac088↗
  2. Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. Co-author DOI 10.1245/s10434-023-13383-w↗
  3. Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden. Co-author DOI 10.3389/fonc.2023.1118633↗
  4. Identification of 2 Chinese Primary Pancreatic Ductal Adenocarcinoma Cancer Cell Lines and Their Phenotypes. Co-author DOI 10.1097/mpa.0000000000001932↗
  5. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2020.01.001↗
  6. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  7. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. Co-author DOI 10.1038/s41416-019-0595-2↗
  8. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Co-author DOI 10.1186/s12943-017-0689-5↗
  9. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway. Co-author DOI 10.1016/j.canlet.2016.06.011↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 7 shared papers, 2016–2023 · strength 0.79
  2. Qi Zhang · 6 shared papers, 2016–2023 · strength 0.76
  3. Xueli Bai · 5 shared papers, 2016–2021 · strength 0.42
  4. Jianxin Wang · 2 shared papers, 2021–2023 · strength 0.34
  5. Tingbo Liang · 2 shared papers, 2020–2023 · strength 0.28
  6. Risheng Que · 2 shared papers, 2020–2023 · strength 0.24
  7. Xiang Li · 2 shared papers, 2020 · strength 0.22
  8. Mengyao Dai · 1 shared paper, 2023 · strength 0.22
  9. Mao Ye · 2 shared papers, 2019–2020 · strength 0.21
  10. Hangyu Zhang · 1 shared paper, 2023 · strength 0.18
  11. Zhou Tong · 1 shared paper, 2023 · strength 0.18
  12. Peng Zhao · 1 shared paper, 2023 · strength 0.18
  13. Yiwen Chen · 2 shared papers, 2016–2020 · strength 0.18
  14. Xiang Li Ma · 1 shared paper, 2023 · strength 0.15
  15. Min Zhang · 1 shared paper, 2023 · strength 0.15
  16. Tao Wei · 2 shared papers, 2017–2019 · strength 0.15
  17. Xueli Bai · 1 shared paper, 2020 · strength 0.13
  18. Tao Ma · 1 shared paper, 2020 · strength 0.09
  19. Wei Chen · 1 shared paper, 2020 · strength 0.09
  20. Tianyu Tang · 1 shared paper, 2020 · strength 0.09
  21. Xiaowei Dang · 1 shared paper, 2019 · strength 0.08
  22. Qi Chen · 1 shared paper, 2019 · strength 0.08
  23. Qi Zhang · 1 shared paper, 2019 · strength 0.08
  24. Xiaozhen Zhang · 1 shared paper, 2019 · strength 0.08
  25. Qi Chen · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.